Redx Pharma Selects Drug Candidate To Treat Leukaemia

Thu, 20th Oct 2016 08:33

LONDON (Alliance News) - Drug development firm Redx Pharma PLC on Tuesday said it has identified a candidate for its leukaemia programme.

The RX005 compound has the potential to treat patients suffering from chronic lymphocytic leukaemia, including those who become resistant to the increasingly used treatment ibrutinib, Redx said.

Redx will now progress studies to prepare the RX005 programme for its first in-human clinical trials, expected to start in early 2018.

Shares in Redx were up 6.8% to 51.00 pence on Thursday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Related Shares

More News

19 Apr 2024 16:02

IN BRIEF: Redx Pharma shareholders approve AIM delisting plans

Redx Pharma PLC - clinical-stage biotechnology company - Shareholders pass resolution by 99.75% margin at general meeting to approve cancelling shares...

12 Apr 2024 15:35

Director dealings: Redx Pharma CEO ups stake

(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stag...

2 Apr 2024 16:57

LONDON MARKET CLOSE: Europe down after Easter holiday weekend

(Alliance News) - The FTSE 100 took a hit on Tuesday, after a boost from London's miners and oil firms were not enough to lift the index.

2 Apr 2024 12:15

Redx Pharma plummets on plans to delist from AIM

(Alliance News) - Redx Pharma PLC shares fell on Tuesday, after it said it intends to cancel its shares from trading on AIM in London.

2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data ac...